Search results
Results from the WOW.Com Content Network
Venetoclax is also indicated as part of a combination therapy for acute myeloid leukemia (AML). [7] For this purpose it is used with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed adults who are age 75 years or older, or those with other health problems where intensive chemotherapy cannot be used.
As of 2015, ponatinib is available in England for the treatment of chronic myeloid leukemia (chronic phase, accelerated phase or blast phase) and Philadelphia-positive acute lymphoblastic leukemia in patients with documented T315I mutation under the Cancer Drugs Fund, [20] and has not been appraised by the National Institute for Health and Care ...
CLL is the most common type of leukemia in the UK, accounting for 38% of all leukemia cases. Approximately 3,200 people were diagnosed with the disease in 2011. [91] In Western populations, subclinical "disease" can be identified in 3.5% of normal adults, [92] and in up to 8% of individuals over the age of 70. [93]
Myelosuppression, anaphylaxis, radiation recall, hepatotoxicity and hepatic sinusoidal obstruction syndrome (common in Wilms' tumour). Estramustine: PO: Antimicrotubule and oestrogenic actions: Prostate cancer.
Non-Hodgkin’s lymphoma (NHL) is one of the most common forms of blood cancer.1 The American Cancer Society estimates that about 81,560 people in the U.S. will be diagnosed with NHL and about ...
[4] [5] It most commonly occurs in older adults. [2] Males are affected more often than females. [2] The five-year survival rate is about 35% in people under 60 years old and 10% in people over 60 years old. [3] Older people whose health is too poor for intensive chemotherapy have a typical survival of five to ten months. [3]
Acute forms of leukemia are the most common forms of leukemia in children. Chronic leukemia is characterized by the excessive buildup of relatively mature, but still abnormal, white blood cells (or, more rarely, red blood cells). Typically taking months or years to progress, the cells are produced at a much higher rate than normal, resulting in ...
Anthracyclines remain some of the most widely used chemotherapeutic agents but their potential is limited by its dose-limiting toxicities. Currently, there are many studies being conducted in the search for anthracyclines with better anti-tumour efficacy or with reduced side effects using different nanotechnology-based drug delivery systems.